{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:11:04Z","timestamp":1768993864820,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ahj.2004.09.047","type":"journal-article","created":{"date-parts":[[2005,4,11]],"date-time":"2005-04-11T17:56:01Z","timestamp":1113242161000},"page":"408-413","source":"Crossref","is-referenced-by-count":98,"title":["Rationale\u2014Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease"],"prefix":"10.1016","volume":"149","author":[{"given":"T.-Christian H.","family":"Mix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ivanovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.G.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Stehman-Breen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2004.09.047_bib1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.09.047_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib12","first-page":"S14","article-title":"The hemoglobin link to adverse outcomes","volume":"3","author":"Collins","year":"2003","journal-title":"Adv. Stud. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib13","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1046\/j.1523-1755.1999.00773.x","article-title":"Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency","volume":"56","author":"Culleton","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"Manjunath","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2004.09.047_bib15","doi-asserted-by":"crossref","first-page":"I80","DOI":"10.1161\/01.HYP.13.5_Suppl.I80","article-title":"Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group","volume":"13","author":"Shulman","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2004.09.047_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.09.047_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.09.047_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1523-1755.2003.00109.x","article-title":"Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study","volume":"64","author":"Abramson","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0272-6386(99)70118-6","article-title":"Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin","volume":"34","author":"Levin","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2004.09.047_bib22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1097\/01.ASN.0000018409.45834.FA","article-title":"Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study","volume":"13","author":"McClellan","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ahj.2004.09.047_bib23","author":"McMurray","year":"2004"},{"key":"10.1016\/j.ahj.2004.09.047_bib24","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahj.2004.09.047_bib26","series-title":"United States Renal Data System: USRDS 2002 annual data report","year":"2002"},{"key":"10.1016\/j.ahj.2004.09.047_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. B","key":"10.1016\/j.ahj.2004.09.047_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_B.2","article-title":"Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study","volume":"15","author":"Moye","year":"1994","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahj.2004.09.047_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","article-title":"The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease","volume":"28","author":"Foley","year":"1996","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.ahj.2004.09.047_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/14.suppl_2.29","article-title":"What are the short-term and long-term consequences of anaemia in CRF patients?","volume":"14","author":"Mann","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahj.2004.09.047_bib31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1523-1755.2004.00425.x","article-title":"Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients","volume":"65","author":"Li","year":"2004","journal-title":"Kidney Int."},{"issue":"Suppl. 4","key":"10.1016\/j.ahj.2004.09.047_bib32","first-page":"2221","article-title":"Influence of renal function on one year cardiovascular outcomes in the VALIANT trial","volume":"108","author":"Anavekar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.09.047_bib33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1523-1755.2004.00863.x","article-title":"Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy","volume":"66","author":"Mohanram","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney Int."},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2004.09.047_bib35","first-page":"S182","article-title":"K\/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000","volume":"37","year":"2001","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.ahj.2004.09.047_bib36","first-page":"1","article-title":"European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Working Party for the European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure","volume":"14","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahj.2004.09.047_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahj.2004.09.047_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/ajkd.2002.34912","article-title":"Health care resource utilization and the impact of anemia management in patients with chronic kidney disease","volume":"40","author":"London","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib39","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1046\/j.1523-1755.2001.00002.x","article-title":"Trends in anemia at initiation of dialysis in the United States","volume":"60","author":"Obrador","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.ahj.2004.09.047_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-8703(99)70401-1","article-title":"Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction","volume":"137","author":"Sadowski","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ahj.2004.09.047_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199707103370201","article-title":"Trial of calcium to prevent preeclampsia","volume":"337","author":"Levine","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/01.CIR.88.2.492","article-title":"Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the Flosequinan-ACE Inhibitor trial (FACET)","volume":"88","author":"Massie","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.09.047_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0735-1097(93)90816-J","article-title":"Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal investigators of the REFLECT study","volume":"22","author":"Packer","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahj.2004.09.047_bib45","first-page":"I","article-title":"Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study","volume":"88","author":"Packer","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.09.047_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0167-5273(01)00447-8","article-title":"The underreporting of results and possible mechanisms of \u2018negative\u2019 drug trials in patients with chronic heart failure","volume":"80","author":"van Veldhuisen","year":"2001","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ahj.2004.09.047_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1056\/NEJM199307153290301","article-title":"Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group","volume":"329","author":"Feldman","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/hrt.72.3.226","article-title":"Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators","volume":"72","author":"Cowley","year":"1994","journal-title":"Br. Heart J."},{"key":"10.1016\/j.ahj.2004.09.047_bib49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0272-6386(89)80149-0","article-title":"The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial","volume":"14","author":"Kleinman","year":"1989","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-110-2-108","article-title":"Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial","volume":"110","author":"Lim","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0272-6386(12)80290-3","article-title":"Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US recombinant human erythropoietin predialysis study group","volume":"18","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahj.2004.09.047_bib52","series-title":"The Cochrane library","article-title":"Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease","author":"Strippoli","year":"2004"},{"key":"10.1016\/j.ahj.2004.09.047_bib53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib54","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ahj.2004.09.047_bib55","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.09.047_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00003246-200102000-00001","article-title":"Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?","volume":"29","author":"Hebert","year":"2001","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group","volume":"340","author":"Hebert","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahj.2004.09.047_bib58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 2","key":"10.1016\/j.ahj.2004.09.047_bib59","first-page":"ii1","article-title":"Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure","volume":"19","year":"2004","journal-title":"Nephrol. Dial. Transplant."}],"updated-by":[{"DOI":"10.1016\/j.ahj.2005.06.022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000}}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304007446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304007446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T12:59:25Z","timestamp":1548593965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870304007446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0002870304007446"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2004.09.047","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}